Tetrahydronaphthalene derivative
AssigneesAtransen Pharma Ltd., Stella Pharma Corporation, Osaka University
InventorsYoshikatsu KANAI, Kohki UEHARA, Yoichiro OHTA, Hiroshi TAKENAKA, Shin MASUI
Life of this patent
Estimating the term…
Loading patent…
AssigneesAtransen Pharma Ltd., Stella Pharma Corporation, Osaka University
InventorsYoshikatsu KANAI, Kohki UEHARA, Yoichiro OHTA, Hiroshi TAKENAKA, Shin MASUI
Estimating the term…
Provided is a tetrahydronaphthalene derivative that can be used as an LAT1-selective inhibitor and an LAT1-selective substrate. The present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. In formula (I), M represents S, O, NH or the like; R1C represents any one structure selected from the group consisting of a 5- to 7-membered aromatic heterocyclic group having a substituent, a C5- to 7-membered aromatic cyclic group having a substituent and a substituted or unsubstituted 8- to 16-membered polycyclic group, or the like; and n represents an integer of 0 to 5. The present invention also relates to a composition for treating cancer, a medicine for BNCT, a diagnostic drug for cancer, an LAT1-selective inhibitor, or a composition for enhancing a BNCT effect, each containing the compound or the pharmaceutically acceptable salt thereof.
A compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof:
A composition for cancer treatment, containing a compound represented by Formula (II) below or a pharmaceutically acceptable salt thereof:
A drug for BNCT, containing a compound represented by Formula (III) below or a pharmaceutically acceptable salt thereof:
A cancer diagnostic agent, containing a compound represented by Formula (IV) below or a pharmaceutically acceptable salt thereof:
Dependencies are inferred from the claim text.